Market Cap 4.90B
Revenue (ttm) 0.00
Net Income (ttm) -446.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.30
Volume 1,991,000
Avg Vol 2,349,514
Day's Range N/A - N/A
Shares Out 186.75M
Stochastic %K 73%
Beta 1.07
Analysts Strong Sell
Price Target $39.40

Company Profile

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifyi...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 786 8230
Fax: 781 786 8866
Address:
1560 Trapelo Road, Waltham, United States
mymoneygone
mymoneygone Aug. 9 at 11:22 PM
$CAPR $DYN https://www.fdatracker.com/fda-calendar/ How legit is fdatracker? I thought the pdufa for $DYN was 01-21-2027.
2 · Reply
monoksop
monoksop Jul. 30 at 10:06 PM
$SRPT Re-entered. DMD story slowly wanes as $DYN starts to take share from Exondys in 2027. Given 51 is responsible for half of the PMO revenue, that slowly bleeds down to around $650M/year by 2030. Elevidys, even with cohort 8, will be much the same, slow bleed with other treatments becoming available, some potential for minor upside in non-amb, but wouldn’t count on it. All in all, should be enough to carry water until the ~$800M convertible notes come due in 2030 (notes could also be refinanced with favourable terms if DM1/FSHD data is good) and siRNA revenue starts to trickle in. Which means it’s all about siRNA now, and with DUX4 knockdown in FSHD at ~92% (del-brax at ~50% for comparison) and DMPK knockdown in DM1 at ~50% in the lowest dose cohort (del-desiran at ~45% for comparison), think there’s a clear path to having a best-in-class asset in FSHD and at the very least a competitive, if not quite differentiated, asset in DM1—all depends on the splicing data. Looking for $28.
3 · Reply
Crush_it
Crush_it Jul. 30 at 7:36 PM
$DYN It is because DYN will most likely be the "SOC" standard of care.
0 · Reply
nyzgujuboi89
nyzgujuboi89 Jul. 30 at 5:59 PM
$SRPT market cap $1.6B and rev 1.2-1.5B (sitting on $900M cash) $DYN $0 rev and market cap $4.6B Make it make sense!
1 · Reply
fda_tracker
fda_tracker Jul. 30 at 2:56 PM
$DYN New PDUFA Date 2026-08-22 Dyne Therapeutics, Inc. Link: https://www.sec.gov/Archives/edgar/data/1818794/000119312526323639/dyn-20260630.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
AXLFI_HQ
AXLFI_HQ Jul. 29 at 10:34 PM
$DYN Specialized companies across aerospace, defense, industrial technology, biotechnology, and digital asset sectors are executing strategic growth initiatives through acquisitions, product portfolio expansion, and market diversification. Learn more: https://axlfi.com/themes/469
0 · Reply
Mmiddleb
Mmiddleb Jul. 28 at 7:33 PM
0 · Reply
Yashinvest
Yashinvest Jul. 28 at 7:37 AM
$DYN Monthly chart, potential price doubling
0 · Reply
Sam201
Sam201 Jul. 27 at 7:36 PM
$DYN This didn't go well.. shorted more today.
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 27 at 1:44 AM
Top Stocks To Watch Tomorrow (July 27, 2026): $DYN $ARLP $FFIV $CLS $BOH https://truthsandnews.com/markets/top-10-stocks-to-watch-tomorrow-july-27-2026-monday
0 · Reply
Latest News on DYN
Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)

2026-07-29T21:00:34.000Z - 11 days ago

Dyne Therapeutics reports Q2 EPS ($1.08), consensus (75c)


Dyne Therapeutics Quarterly report: Q2 2026

Jul 29, 2026, 7:00 AM EDT - 12 days ago

Dyne Therapeutics Quarterly report: Q2 2026


Dyne Therapeutics Earnings release: Q2 2026

Jul 29, 2026, 7:00 AM EDT - 12 days ago

Dyne Therapeutics Earnings release: Q2 2026


Dyne Therapeutics 18.3M share Spot Secondary priced at $20.50

2026-07-22T04:05:08.000Z - 19 days ago

Dyne Therapeutics 18.3M share Spot Secondary priced at $20.50


Dyne Therapeutics announces $300M common stock offering

2026-07-21T20:50:16.000Z - 19 days ago

Dyne Therapeutics announces $300M common stock offering


Dyne Therapeutics initiated with a Buy at TD Cowen

2026-06-26T10:05:06.000Z - 6 weeks ago

Dyne Therapeutics initiated with a Buy at TD Cowen


Biotech ETF Index Surges 10% After Rebalance

Jun 25, 2026, 11:31 AM EDT - 6 weeks ago

Biotech ETF Index Surges 10% After Rebalance

ALKS APGE DFTX KLRA KYMR MANE MIRM


Dyne Therapeutics Appoints Barry Greene to Board of Directors

Jun 22, 2026, 4:10 PM EDT - 6 weeks ago

Dyne Therapeutics Appoints Barry Greene to Board of Directors


Dyne Therapeutics Slides: AGM presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Dyne Therapeutics Slides: AGM presentation


Dyne Therapeutics Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Dyne Therapeutics Quarterly report: Q1 2026


Dyne Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Dyne Therapeutics Earnings release: Q1 2026


Dyne Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Dyne Therapeutics Proxy statement: Proxy filing


Dyne Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 3 months ago

Dyne Therapeutics Proxy statement: Proxy filing


Dyne Therapeutics Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Dyne Therapeutics Proxy statement: Proxy filing


Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 4:00 PM EDT - 5 months ago

Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum


Dyne Therapeutics Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

Dyne Therapeutics Earnings release: Q4 2025


Dyne Therapeutics Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

Dyne Therapeutics Annual report: Q4 2025


Dyne Therapeutics Annual report: Q4 2025

Mar 2, 2026, 7:00 AM EST - 5 months ago

Dyne Therapeutics Annual report: Q4 2025


Dyne Therapeutics Slides: Corporate presentation

Mar 2, 2026, 6:00 AM EST - 5 months ago

Dyne Therapeutics Slides: Corporate presentation


Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

Dec 23, 2025, 7:30 AM EST - 8 months ago

Dyne Therapeutics Appoints Vikram Karnani to Board of Directors


Dyne Therapeutics Transcript: Study Result

Dec 8, 2025, 8:00 AM EST - 8 months ago

Dyne Therapeutics Transcript: Study Result


Dyne Therapeutics Press release: Study Result

Dec 8, 2025, 8:00 AM EST - 8 months ago

Dyne Therapeutics Press release: Study Result


Dyne Therapeutics Slides: Study Result

Dec 8, 2025, 8:00 AM EST - 8 months ago

Dyne Therapeutics Slides: Study Result


Dyne Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 9:20 AM EST - 9 months ago

Dyne Therapeutics Transcript: Stifel 2025 Healthcare Conference


Dyne Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Dyne Therapeutics Earnings release: Q3 2025


Dyne Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 9 months ago

Dyne Therapeutics Quarterly report: Q3 2025


Dyne Therapeutics to Present at Upcoming Investor Conferences

Nov 3, 2025, 7:30 AM EST - 9 months ago

Dyne Therapeutics to Present at Upcoming Investor Conferences


Dyne Therapeutics Earnings release: Q2 2025

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Dyne Therapeutics Earnings release: Q2 2025


Dyne Therapeutics Quarterly report: Q2 2025

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Dyne Therapeutics Quarterly report: Q2 2025


Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

Jul 16, 2025, 7:00 AM EDT - 1 year ago

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer


Dyne Therapeutics Transcript: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Dyne Therapeutics Transcript: Status Update


Dyne Therapeutics Press release: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Dyne Therapeutics Press release: Status Update


Dyne Therapeutics Slides: Status Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Dyne Therapeutics Slides: Status Update


Dyne Therapeutics Slides: Investor Presentation

Jun 16, 2025, 9:12 PM EDT - 1 year ago

Dyne Therapeutics Slides: Investor Presentation


Dyne Therapeutics Earnings release: Q1 2025

May 8, 2025, 12:30 PM EDT - 1 year ago

Dyne Therapeutics Earnings release: Q1 2025


Dyne Therapeutics Quarterly report: Q1 2025

May 8, 2025, 12:30 PM EDT - 1 year ago

Dyne Therapeutics Quarterly report: Q1 2025


mymoneygone
mymoneygone Aug. 9 at 11:22 PM
$CAPR $DYN https://www.fdatracker.com/fda-calendar/ How legit is fdatracker? I thought the pdufa for $DYN was 01-21-2027.
2 · Reply
monoksop
monoksop Jul. 30 at 10:06 PM
$SRPT Re-entered. DMD story slowly wanes as $DYN starts to take share from Exondys in 2027. Given 51 is responsible for half of the PMO revenue, that slowly bleeds down to around $650M/year by 2030. Elevidys, even with cohort 8, will be much the same, slow bleed with other treatments becoming available, some potential for minor upside in non-amb, but wouldn’t count on it. All in all, should be enough to carry water until the ~$800M convertible notes come due in 2030 (notes could also be refinanced with favourable terms if DM1/FSHD data is good) and siRNA revenue starts to trickle in. Which means it’s all about siRNA now, and with DUX4 knockdown in FSHD at ~92% (del-brax at ~50% for comparison) and DMPK knockdown in DM1 at ~50% in the lowest dose cohort (del-desiran at ~45% for comparison), think there’s a clear path to having a best-in-class asset in FSHD and at the very least a competitive, if not quite differentiated, asset in DM1—all depends on the splicing data. Looking for $28.
3 · Reply
Crush_it
Crush_it Jul. 30 at 7:36 PM
$DYN It is because DYN will most likely be the "SOC" standard of care.
0 · Reply
nyzgujuboi89
nyzgujuboi89 Jul. 30 at 5:59 PM
$SRPT market cap $1.6B and rev 1.2-1.5B (sitting on $900M cash) $DYN $0 rev and market cap $4.6B Make it make sense!
1 · Reply
fda_tracker
fda_tracker Jul. 30 at 2:56 PM
$DYN New PDUFA Date 2026-08-22 Dyne Therapeutics, Inc. Link: https://www.sec.gov/Archives/edgar/data/1818794/000119312526323639/dyn-20260630.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
AXLFI_HQ
AXLFI_HQ Jul. 29 at 10:34 PM
$DYN Specialized companies across aerospace, defense, industrial technology, biotechnology, and digital asset sectors are executing strategic growth initiatives through acquisitions, product portfolio expansion, and market diversification. Learn more: https://axlfi.com/themes/469
0 · Reply
Mmiddleb
Mmiddleb Jul. 28 at 7:33 PM
0 · Reply
Yashinvest
Yashinvest Jul. 28 at 7:37 AM
$DYN Monthly chart, potential price doubling
0 · Reply
Sam201
Sam201 Jul. 27 at 7:36 PM
$DYN This didn't go well.. shorted more today.
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 27 at 1:44 AM
Top Stocks To Watch Tomorrow (July 27, 2026): $DYN $ARLP $FFIV $CLS $BOH https://truthsandnews.com/markets/top-10-stocks-to-watch-tomorrow-july-27-2026-monday
0 · Reply
ciggycapital
ciggycapital Jul. 24 at 1:16 PM
$DYN ouch!!!
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:03 PM
Cantor🏁 $DYN and said -- We are initiating coverage of Dyne Therapeutics (NASDAQ: DYN) with an Overweight rating. $SRPT CAPR SLDB PTCT $RNA PEPG SNY IONS Here's what else Cantor had to say in its initiation report: https://x.com/Quantumup1/status/2080262413471953360?s=20
0 · Reply
EquityResearch6
EquityResearch6 Jul. 22 at 1:34 PM
Biggest Movers Today Gainers $SMCI +15% — Raised Q4 gross margin outlook to 15%-17% vs. prior 8.2%-8.4%. The company reported $60B+ in new Q4 orders and record backlog, showing strong AI server demand and improving margins. $OKLO +4%, XE +3% — Advanced nuclear stocks moved higher after reports of participation in a $200M U.S. program supporting faster nuclear deployment for AI data centers. AI power demand remains a major long-term theme. $RKLB +4% — Won a $266M U.S. government contract for 12 suborbital launches, with options for 6 more through 2028, strengthening its defense and space backlog. Losers $PEGA -15% — Missed earnings and revenue estimates as AI uncertainty delayed enterprise software spending. $DYN -10% — Fell after a $375M stock offering, with investors reacting to dilution concerns. Today's market continues rewarding AI infrastructure, power, and space themes while pressuring companies facing slower demand or dilution risks.
0 · Reply
G101SPM
G101SPM Jul. 22 at 12:46 PM
#DILUTION FedEx ($FDX) files mixed securities shelf offering FuelCell Energy ($FCEL) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 on July 21 Dyne ( $DYN) prices upsized 18.3 mln-share common stock offering at $20.50/share
0 · Reply
notreload_ai
notreload_ai Jul. 22 at 10:05 AM
$DYN announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029. https://notreload.xyz/xy/dyn-prices-375m-upsized-public-offering/
0 · Reply
theflynews
theflynews Jul. 22 at 12:27 AM
Closing Bell Movers: Finward jumps after First Financial deal - $DYN - https://thefly.com/DYN
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 22 at 12:06 AM
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock $DYN $VTI $XBI https://stocktwits.com/news/equity/markets/why-dyn-shares-are-down-10-after-hours-day-after-an-fda-win-another-announcement-rocks-stock/cZZlyl0R7wc
0 · Reply
Sam201
Sam201 Jul. 21 at 11:37 PM
$DYN short this! this should see 18 or below soon.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 21 at 10:37 PM
$OZK $WAL $FFAI $DYN AFTER-HOURS MOVERS: Currently Higher After Earnings: - Annaly Capital (NLY) up 1.0% Currently Also Higher: - Finward Bancorp (FNWD) up 20.6% after agreeing to be acquired by First Financial (FFBC) in an all-stock transaction - Super Micro (SMCI) up 17.6% after guiding for Q4 revenue at the low end of its previously provided guidance range Currently Lower After Earnings: - Pegasystems (PEGA) down 12.7% - Alaska Air (ALK) down 1.5% - Bank OZK (OZK) down 2.0% - Western Alliance (WAL) down 1.2% Currently Also Lower: - Faraday Future (FFAI) down 24.8% after announcing it will effect a 1-for-50 reverse split of its Class A Common Stock and Class B common stock on July 24 - Dyne Therapeutics (DYN) down 11.2% after announcing a $300M common stock offering.
0 · Reply
InItToWinIt100
InItToWinIt100 Jul. 21 at 9:32 PM
7/21 After Hours Movers $SNDK $DELL $AEHL $PEGA $DYN https://www.trade-ideas.com/share.php?code=OpbsUZ0VHBj3ETDOdz9SS60Mh90ZFSaC
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 21 at 8:04 PM
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space $SRPT $DYN https://stocktwits.com/news/equity/markets/srpt-stock-drops-4-as-citi-flags-potentially-stronger-rival-in-duchenne-space/cZZSZgtR7vU
0 · Reply
yus37
yus37 Jul. 21 at 6:28 PM
$SRPT is one of the strangest valuations in biotech. ~$2.2B annual revenue. Profitable. Commercial products. Yet only a ~$1.7B market cap. Yes, $DYN is a serious competitor and ELEVIDYS still carries major uncertainty. Those risks are real. But at today's valuation, it feels like the market is already pricing in a lot of bad news. If Sarepta stabilizes, the upside could be significant. 🧬📈 $XBI
2 · Reply